Mural Oncology plc(MURA) - 2023 Q4 - Annual Results

Exhibit 99.1 Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update Lead product candidate, nemvaleukin, is being developed to treat a wide range of solid tumors and is currently in two potentially registrational clinical trials with readouts for both expected in 1H 2025 Newly recommended phase 2 dose of nemvaleukin with increased dosage and less frequent dosing schedule to be explored in a cohort of ARTISTRY-6, the company's ongoing phase 2 trial in patient ...